New HIV pill STP0404 shows promise in small trial
NCT ID NCT05869643
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2a trial tested a new experimental drug called STP0404 (Pirmitegravir) in 25 adults with HIV-1 who had never taken HIV medications before. Participants received either a low, medium, or high dose of STP0404 or a placebo once daily for 10 days. The study measured how well the drug lowered the amount of virus in the blood and checked for any side effects. The goal is to see if STP0404 can be a safe and effective new option for controlling HIV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
STP0404 (Pirmitegravir)
What this could lead to
If successful, this could lead to a new daily pill to control HIV-1, offering another treatment option for people living with HIV.
What could go wrong
This is a small, early-phase trial (25 people) testing short-term effects over 10 days. It may not show strong enough antiviral activity or could have side effects. Larger studies are needed to confirm safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atrium Health Wake Forest Baptist Medical Center - PPDS
Winston-Salem, North Carolina, 27157, United States
-
Be Well Medical Center
Berkley, Michigan, 48072, United States
-
Kaiser Permenente Los Angeles Medical Center
Los Angeles, California, 90027, United States
-
Midway Immunology and Research Center
Ft. Pierce, Florida, 34982, United States
-
North Shore University Hospital
Manhasset, New York, 11030-3816, United States
-
North Texas Infectious Diseases Consultants, P.A.
Dallas, Texas, 75246, United States
-
Orlando Immunology Center
Orlando, Florida, 32803, United States
-
Ruane Clinical Research, Inc.
Los Angeles, California, 90036, United States
-
Saint Michael's Medical Center
Newark, New Jersey, 07102, United States
-
Schiff Center for Liver Diseases/University of Miami
Miami, Florida, 33136-2107, United States
-
South Jersey Infectious Disease
Somers Point, New Jersey, 08244, United States
-
St Hope Foundation, Inc
Bellaire, Texas, 77401, United States
-
USF Health South Tampa Center for Advanced Healthcare
Tampa, Florida, 33602-3511, United States